Clinical trial
Study To Assess Long Term Safety Of Pazopanib
NCT00387205 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00387205 |
|---|---|
| Title | Study To Assess Long Term Safety Of Pazopanib |
| Official title | An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Pazopanib |
| Enrollment | 188 |
| Start date | Jun 20, 2006 |
| Primary completion | Feb 13, 2013 |
| Completion | Mar 8, 2018 |
| First posted | Oct 12, 2006 |
| Last update posted | Mar 6, 2019 |
| Countries | France, Singapore, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: